l General Information |
Product Name | Ceritinib |
General description | Ceritinib is an orally available inhibitor of the receptor tyrosine kinase activity of anaplastic lymphoma kinase (ALK) with antineoplastic activity. |
Synonym | LDK378 |
Purity | ≥98%(HPLC) | CAS Number | 1032900-25-6 |
Formula | C28H36ClN5O3S | Molecular Weight | 558.138 |
Suitability | BioReagent, suitable for cell culture, etc. |
l Physical and Chemical Information |
Appearance | White or Off-white solid |
Solubility(25℃) | DMSO | ≥15mg/mL |
Ethanol | ~3mg/mL |
Water | Insoluble |
l Biological Information |
Biochem/Physiol Actions | Ceritinib is an orally available inhibitor of the receptor tyrosine kinase activity of anaplastic lymphoma kinase (ALK) with antineoplastic activity. Upon administration, ceritinib binds to and inhibits wild-type ALK kinase, ALK fusion proteins and ALK point mutation variants. Inhibition of ALK leads to both the disruption of ALK-mediated signaling and the inhibition of cell growth in ALK overexpressing tumor cells. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development. ALK dysregulation and gene rearrangements are associated with a variety of tumor cell types. |
Application | 1. Antineoplastic Agents 2. Protein Kinase Inhibitors |
l Packaging & Storage |
Packaging | 10mg; 50mg; 250mg |
Storage temp. | -20℃ |
l Precautions and Disclaimer |
This product is for R&D use only, not for drug, household, or other uses. |
l References |
1. http://www.drugbank.ca 2. https://ncit.nci.nih.gov 3. https://www.ncbi.nlm.nih.gov |
